Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (281-290 of 302) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.
American Journal of Obstetrics and Gynecology|August 11, 2018
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 StudyAshley S Felix, David E Cohn, Theodore M Brasky, et al.
Cancer Research|August 4, 2006
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patientsHeather Hampel, Wendy Frankel, Jenny Panescu, et al.
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
Cancer|June 28, 2017
Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patientsNicholas W Bateman, Elizabeth A Dubil, Guisong Wang, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Journal of the National Cancer Institute|April 5, 2017
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and RecurrenceTheodore M Brasky, Ashley S Felix, David E Cohn, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Gynecologic Oncology|January 29, 2023
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient populationPaulina J Haight, David A Barrington, Stephen M Graves, et al.
Pageof 31

Showing results (281-290 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.
American Journal of Obstetrics and Gynecology|August 11, 2018
Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 StudyAshley S Felix, David E Cohn, Theodore M Brasky, et al.
Cancer Research|August 4, 2006
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patientsHeather Hampel, Wendy Frankel, Jenny Panescu, et al.
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
Cancer|June 28, 2017
Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patientsNicholas W Bateman, Elizabeth A Dubil, Guisong Wang, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Journal of the National Cancer Institute|April 5, 2017
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and RecurrenceTheodore M Brasky, Ashley S Felix, David E Cohn, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Gynecologic Oncology|January 29, 2023
Safety and feasibility of same-day discharge following minimally invasive hysterectomy in the morbidly obese patient populationPaulina J Haight, David A Barrington, Stephen M Graves, et al.
Pageof 31